Phase I Trial of Intratumoral Administration of NIS-Expressing Strain of Measles Virus in Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor

Abstract

Study approved by Mayo IRB on April 18, 2016, and by USAMRMC/ORP/HRPO on May 6, 2016. All study staff completed IRB training. Dose volume charts have been developed to facilitate pharmacy orders. Study opened for enrollment on May 17, 2016. Study coordinators identified and assigned to the study by Mayo Clinic Cancer Center. Five patients have been enrolled in the study. They completed treatment per protocol and continue the follow up. None of the treated patients experienced side effects. With the first 3 patients we have completed the first dose level, and two patients have been treated by dose 2 level. Accrual of the third patient into dose 2 is ongoing. So far out of 5 treated patients two died to cancer progression. Others are undergoing follow up. A few additional patients are under evaluation for eligibility at this time.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2020
Accession Number
AD1120858

Entities

People

  • Dusica Babovic-vuksanovic

Organizations

  • Mayo Clinic

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Clinical Trials
  • Department Of Defense
  • Diseases And Disorders
  • Electronic Mail
  • Gene Expression
  • Health Services
  • Information Operations
  • Law
  • Maryland
  • Neoplasms
  • Neurofibromatosis
  • Oncolytic Viruses
  • Patent Applications
  • Peripheral Nervous System
  • Pharmacies
  • Professional Development
  • Side Effects
  • Standards
  • Technology Transfer
  • Therapy
  • Training
  • Viruses

Fields of Study

  • Medicine

Readers

  • Medical Imaging.
  • Oncology
  • Oncology and Biomarker-Based Cancer Detection.